CoChat

Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation

Open access

The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.

Abstract

Inhibitors of the mitochondrial respiratory chain complex I are suggested to exert anti-tumor activity on those tumors relying on oxidative metabolism and are therefore of interest to oncology research. Nevertheless, the safety profile of these inhibitors should be thoroughly assessed. Rotenone, a proven complex I inhibitor, has shown anti-carcinogenic activity in several studies. In this context rotenone was used in this study as a tool compound with the aim to identify suitable biomarker candidates and provide enhanced mechanistic insights into the molecular and cellular effects of complex I inhibitors. Rats were treated with 400 ppm rotenone daily for 1, 3 or 14 consecutive days followed by necropsy. Classical clinical endpoints, including hematology, clinical chemistry and histopathology with supporting investigations (FACS-analysis, enzymatic activity assays) were examined as well as gene expression analysis. Through these investigations, we identified liver, bone marrow and bone as target organs amongst approx. 40 organs evaluated at least histopathologically. Our results suggest blood analysis, bone marrow parameters, assessment of lactate in serum and glycogen in liver, and especially gene expression analysis in liver as useful parameters for an experimental model to help to characterize the profile of complex I inhibitors with respect to a tolerable risk-benefit balance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep45465

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Complex I inhibition. Complex I activity in isolated mitochondria from the livers of control and rotenone treated animals (400 ppm) is shown as mean with SD (n = 5) after the three treatment durations. Statistical significance (Two-Way ANOVA with Sidak multiple comparison test) is indicated by ***P < 0.001 compared to time-matched control groups.
Figure 1 Complex I inhibition. Complex I activity in isolated mitochondria from the livers of control and rotenone treated animals (400 ppm) is shown as mean with SD (n = 5) after the three treatment durations. Statistical significance (Two-Way ANOVA with Sidak multiple comparison test) is indicated by ***P < 0.001 compared to time-matched control groups.CC BY · PubMed Central
Figure 2 Changes in the liver after rotenone treatment. (A–C) Histopathological changes in the liver of rats treated with 400 ppm rotenone for 3 (B) and 14 days (C) compared to control (A). Shown are representative hematoxylin and eosin stained liver sections with a scale bar of 50 μm. (D) The enzymatically determined decrease of glycogen content in livers is shown as mean with SD (n = 5) at the three different time-points. (E) Decreased blood glucose, (F) time dependent increased blood lactate concentrations and (G) other significant blood parameters (alkaline phosphatase (APh), glutamate dehydrogenase (GLDH), triglyceride (TRIGL), urea (UREA)) are also presented as mean with SD (n = 5) at the three different time-points. Statistical analysis was performed with Two-Way ANOVA with Sidak multiple comparison test. Statistical significance is indicated by *P < 0.05, **P < 0.01, and ***P < 0.001 compared with time-matched control groups or by #P < 0.05 for the factor “time” of one treatment group.
Figure 2 Changes in the liver after rotenone treatment. (A–C) Histopathological changes in the liver of rats treated with 400 ppm rotenone for 3 (B) and 14 days (C) compared to control (A). Shown are representative hematoxylin and eosin stained liver sections with a scale bar of 50 μm. (D) The enzymatically determined decrease of glycogen content in livers is shown as mean with SD (n = 5) at the three different time-points. (E) Decreased blood glucose, (F) time dependent increased blood lactate concentrations and (G) other significant blood parameters (alkaline phosphatase (APh), glutamate dehydrogenase (GLDH), triglyceride (TRIGL), urea (UREA)) are also presented as mean with SD (n = 5) at the three different time-points. Statistical analysis was performed with Two-Way ANOVA with Sidak multiple comparison test. Statistical significance is indicated by *P < 0.05, **P < 0.01, and ***P < 0.001 compared with time-matched control groups or by #P < 0.05 for the factor “time” of one treatment group.CC BY · PubMed Central
Figure 3 Rotenone effects on hematopoietic tissue. (A–C) Histopathological changes in the bone marrow of rats treated with 400 ppm rotenone for 3 (B) and 14 days (C) compared to control (A), indicating decreased bone marrow cellularity and an increase in adipocytes after 3 days of treatment (B), with increased severity after 14 days (C). Shown are representative hematoxylin and eosin stained bone marrow sections with a scale bar of 200 μm. (D–G) FACS results of femoral bone marrow, including (D) red progenitor cells, (E) mature red blood cells, (H) myeloid cells and (I) lymphoid cells are shown as percent change (mean with SD, n = 5) at the three different time-points relative to the corresponding time-matched control. (F,G) Representative FACS plots of immature nucleated cells and mature non nucleated cells (blue circle) of a control animal (F) and a rotenone treated animal after 14 days (G). The blue arrow indicates a shift towards more mature erythroid forms. (J) Significantly affected blood cell parameters are presented as mean with SD (n = 5) at the three different time-points. Statistical analysis was performed with Two-Way ANOVA with Sidak multiple comparison test.
Figure 3 Rotenone effects on hematopoietic tissue. (A–C) Histopathological changes in the bone marrow of rats treated with 400 ppm rotenone for 3 (B) and 14 days (C) compared to control (A), indicating decreased bone marrow cellularity and an increase in adipocytes after 3 days of treatment (B), with increased severity after 14 days (C). Shown are representative hematoxylin and eosin stained bone marrow sections with a scale bar of 200 μm. (D–G) FACS results of femoral bone marrow, including (D) red progenitor cells, (E) mature red blood cells, (H) myeloid cells and (I) lymphoid cells are shown as percent change (mean with SD, n = 5) at the three different time-points relative to the corresponding time-matched control. (F,G) Representative FACS plots of immature nucleated cells and mature non nucleated cells (blue circle) of a control animal (F) and a rotenone treated animal after 14 days (G). The blue arrow indicates a shift towards more mature erythroid forms. (J) Significantly affected blood cell parameters are presented as mean with SD (n = 5) at the three different time-points. Statistical analysis was performed with Two-Way ANOVA with Sidak multiple comparison test.CC BY · PubMed Central
Figure 4 The effect of rotenone on bone. (A+B) Histopathological changes in the bone of rats administered with 400 ppm rotenone for 14 days (B) compared to control (A). Shown are representative hematoxylin and eosin stained bone sections of the femur with a higher magnification of the growth plates (scale bar of 1000 μm and 200 μm, respectively).
Figure 4 The effect of rotenone on bone. (A+B) Histopathological changes in the bone of rats administered with 400 ppm rotenone for 14 days (B) compared to control (A). Shown are representative hematoxylin and eosin stained bone sections of the femur with a higher magnification of the growth plates (scale bar of 1000 μm and 200 μm, respectively).CC BY · PubMed Central
Figure 5 Gene expression analysis. (A) Heatmaps represent expression profiles of transcripts significantly affected by rotenone treatment in the liver, heart (left ventricle apex) and brain stem over time. Each column represents a dataset from one organ sample (n = 4), and each row represents a transcript. Changes in gene expression are demonstrated by the color bar to the left of the diagram. Red represents increased and green represents decreased expression levels, indicated as ratios relative to the mean of the time-matched control group. (B–M) Tables show different affected pathways. Arrows represent the direction of deregulation of genes associated with the respective pathway. NDEG (not found as deregulated by our selected cutoffs) indicates that genes belonging to this pathway were not significantly deregulated in the specific organ and time point indicated.
Figure 5 Gene expression analysis. (A) Heatmaps represent expression profiles of transcripts significantly affected by rotenone treatment in the liver, heart (left ventricle apex) and brain stem over time. Each column represents a dataset from one organ sample (n = 4), and each row represents a transcript. Changes in gene expression are demonstrated by the color bar to the left of the diagram. Red represents increased and green represents decreased expression levels, indicated as ratios relative to the mean of the time-matched control group. (B–M) Tables show different affected pathways. Arrows represent the direction of deregulation of genes associated with the respective pathway. NDEG (not found as deregulated by our selected cutoffs) indicates that genes belonging to this pathway were not significantly deregulated in the specific organ and time point indicated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 4

  1. OJEU. Official Journal of European Union. Commission Decision of 8 December 2008 concerning the non-inclusion of certain active substances in Annex I to Council Directive 91/414/EEC and the withdrawal of authorisations for plant protection products containing these substances. L 335/91.13.12.2008. (2008c).
  2. Losco, P. In Pathobiology of the Aging Rat Vol. 1 (eds U. Mohr, D. L. Dungworth & C. C. Capen ) Ch. 75-94, (ILSI Press, 1992).
  3. Fernández-Vizarra, E., Fernández-Silva, P. & Enríquez, J. A. In Cell Biology: A Laboratory Handbook Vol. 2 (ed J. E. Celis ) Ch. 10, 69–77 (2006).
  4. Paxinos, G. & Watson, C. The rat brain in stereotaxic coordinates. 3rd edn, (Academic Press, 1997).

Cited by

See all 335

Metadata

Authors
Heinz, S., Freyberger, A., Lawrenz, B., Schladt, L., Schmuck, G., & Ellinger-Ziegelbauer, H.
Affiliations
Bayer (Germany) (DE)
Corresponding author
Ellinger-Ziegelbauer, Heidrun
Venue
Scientific Reports
Published
2017-04-04
Volume
7
Issue
1
Pages
45465-45465
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2604140695
Cited by
334
References
72
Citations by year
2026: 33 · 2025: 48 · 2024: 43 · 2023: 62 · 2022: 45 · 2021: 42 · 2020: 31 · 2019: 16 · 2018: 12 · 2017: 2
FWCI
6.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
rotenone, mitochondrial complex I inhibitors, electron transport chain, anticancer agents, oxidative metabolism, safety assessment, biomarkers, bone marrow, bone, histopathology, gene expression, lactate, glycogen
MeSH terms
Administration, Oral, Animals, Body Weight, Bone and Bones, Brain, Hematopoiesis, Liver, Male, Mitochondria, Rotenone, Gene Expression, Rats, Wistar, Electron Transport Complex I, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.